Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

A Study of treatments in Her2+ first line metastatic breast cancer

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT04784715?cond=A+Phase+III+Study+of+Trastuzumab+Deruxtecan+%28T-DXd%29+with+or+without+Pertuzumab+versus+Taxane%2C+Trastuzumab+and+Pertuzumab+in+HER2-positive%2C+First-line+Metastatic+Breast+Cancer&draw=1&rank=1